Patricia (Pat) Donahue brings a breadth of expertise gained from over 25 years in global pharmaceutical and biopharmaceutical industries. Her direct experience encompasses product research through clinical development and commercialization, marketing and sales, alliance management and business and corporate development. Pat offers business development services to enhance the competitive position of early to mid-stage biotechnology and pharmaceutical companies. Pat provides business development advice and assistance in: strategic planning and positioning; collaboration management; establishing due diligence activities for asset valuation and licensing, corporate merger and acquisition; the full spectrum of transaction activities on both the buy and sell side. Pat has conducted licensing and due diligence activities for multiple public and emerging biotech companies. Previously, Pat was responsible for identification and in-licensing of orphan drug candidates at Raptor Pharmaceuticals. Prior to that, she was responsible at Takeda Pharmaceuticals for management of the global scouting and evaluation team for in licensing product candidates across three therapeutic areas, created business development processes and tracking metrics, served on the Global Business Development Leadership Committee and participated as a core team member in M&A activities resulting in the $13B acquisition of Nycomed. While at XOMA, Pat closed multiple antibody discovery and development collaboration transactions and was operationally responsible for the XOMA collaboration business each of which helped turn the research function from a cost center to a profit center and provided non-dilutive revenue to enable the proprietary pipeline build. At Merck KGaA, she managed corporate alignment and coordination of global and regional deal activities and while at Dey Labs, an affiliate of Merck KGaA, was responsible for strategic licensing of products. Pat began her career at 3M.